Ref. Ares(2021)1450300 - 24/02/2021
Ref. Ares(2021)2029622 - 22/03/2021
Meeting with EFPIA 
Meeting date and place 
Meeting held on 25/01/2021 10:00 in Videoconference 
Participating organisation(s) & representative(s) 
[Art. 4.1 (b)]  
- - European Federation of Pharmaceutical Industries and Associations (TRN: 38526121292-88)  Participant, 
[Art. 4.1 (b)]  
- - IMC 
Participant, 
[Art. 4.1 (b)]
  - - IMC 
Participant, 
[Art. 4.1 (b)]  
- - IMC 
Participant, 
Main issues discussed 
 
The main purpose of the meeting was for the industry to present their key issues of concern ahead of the EU-Canada Intellectual Property
Dialogue.  
IMC and EFPIA raised as main concerns the patent term restoration implemented by Canada; the modifications done in the Canadian
regulation to integrate the so-called “patent linkage” and the excessive level of liability for lost generic profits.
Directorate or unit 
TRADE B/3 
Internal participants 
[Art. 4.1 (b)]
 
TRADE  B/3 
[Art. 4.1 (b)] @ec.europa.eu) 
Participant, 
[Art. 4.1 (b)]
 
TRADE  B/3 
[Art. 4.1 (b)]
@ec.europa.eu) 
Participant, Notetaker, 
[Art. 4.1 (b)]
 
TRADE  D/1 
[Art. 4.1 (b)]
@ec.europa.eu) 
Participant, 
[Art. 4.1 (b)]
 
TRADE  D/1/DEL/CANADA/002  [Art. 4.1 (b)] @ec.europa.eu) 
Participant, 
[Art. 4.1 (b)]
  TRADE  E/3 
[Art. 4.1 (b)]
@ec.europa.eu)  Participant, 
Author(s) of minutes 
[Art. 4.1 (b)]  
Validator and validation date 
[Art. 4.1 (b)]  validated the minutes on 24/02/2021 10:47 
Minutes generated by EMT (Id:TRADE/1838)
Page 1 of 1

---